The EMPA-REG OUTCOME trial, led by Zinman et al., showed that the SGLT2 inhibitor empagliflozin reduces the risk of cardiovascular death as well as the risk of all-cause mortality and hospitalization for heart failure [29]. This evidence concerns the gene SLC5A2 and heart failure.